Shuang Li

Shuang Li is a seasoned professional in analytical development and quality control, currently serving as the Sr. Director of Analytical Development and Quality Control at Revolution Medicines since September 2025. Prior to this role, Shuang Li held the position of Sr. Director of Analytical Development CMC at ReCode Therapeutics from 2021 to September 2025. Shuang Li's extensive experience includes leadership roles at Genentech, where responsibilities spanned from Head of Analytical Chemistry, Global Analytical Science and Technology to Senior Manager in the same area from 2017 to 2021. Earlier career positions include Research Scientist II at Gilead Sciences, Principal Scientist at Relypsa, Product Analytical Group Leader at Teva Pharmaceuticals, Senior Scientist at Watson Pharmaceuticals, and Research Scientist/Group Leader at PPD.